HIV Drug Resistance: What Mothers and Infants Need to Know
"A study in Burkina Faso reveals the challenges of HIV drug resistance in mothers and infants undergoing antiretroviral treatment, highlighting the need for improved monitoring and treatment strategies."
The ongoing fight against HIV faces a significant hurdle: the emergence of drug resistance. This is especially critical for women and children, where the effectiveness of antiretroviral therapy (ART) can be compromised. Understanding the landscape of HIV drug resistance (HIVDR) is essential for improving treatment strategies and safeguarding the health of future generations.
Mother-to-child transmission (MTCT) remains a key area of concern. While prevention programs have made strides, they haven't eliminated the risk entirely. This makes it vital to monitor drug resistance in both mothers and infants receiving ART to ensure the continued efficacy of treatment regimens. When treatments fail, it leads to resistance.
This article explores the findings of a study conducted in Ouagadougou, Burkina Faso, which investigated HIVDR in mothers and their infants undergoing ART. By examining the types of resistance present and their potential impact, the study sheds light on the challenges and opportunities in combating HIV in vulnerable populations.
The Current Burden of HIV Drug Resistance
In 2023, an estimated 39.9 million people globally were living with HIV, alongside 1.3 million new HIV infections. The WHO's 2024 HIV drug resistance report included pretreatment resistance data from 11 countries. In CDC-supported HIV programs, more than 96% of people receiving antiretroviral therapy were virally suppressed, a level that helps prevent transmission. A 2025 study reported that 82.3% of ART-experienced participants faced barriers to healthcare access and that treatment discontinuation reached 90% in its study population.
Treatment, Testing, and Their Limits
Antiretroviral treatment works only while the virus remains susceptible to the drugs used. NIH guidance notes that the extent of resistance varies with a person's antiretroviral treatment history, ranging from minimal or no resistance to extensive resistance. Resistance testing can help guide therapy, but genotypic test mutations do not always correlate precisely with resistance inside the body. HIV drug resistance can therefore jeopardize antiretroviral effectiveness and contribute to HIV-associated complications and deaths.
From AZT to Combination Therapy
HIV.gov's timeline follows major HIV and AIDS milestones from the first reported cases in 1981 to the present. Within fewer than 30 years of antiretroviral therapy, more than 25 drugs had been developed, beginning with zidovudine, or AZT, in 1987. Combining AZT with another antiretroviral improved treatment effectiveness, although patients often developed resistance. HIV rapidly developed resistance to AZT, demonstrating why single-drug approaches were inadequate.
Decoding HIV Drug Resistance: Key Findings from Burkina Faso
A recent cross-sectional study in Burkina Faso examined HIV drug resistance in 50 mother-infant pairs receiving ART. The study, conducted at Saint Camille Hospital of Ouagadougou, analyzed blood samples from mothers one year after delivery and from infants at 12 months after ART initiation.
- HIV-1 Subtypes: Identifying the different strains of the virus present in the population.
- Drug Resistance Mutations (DRM): Pinpointing specific genetic changes that make the virus less susceptible to antiretroviral drugs.
- Resistance Levels: Classifying the degree of resistance (high, intermediate, low) to commonly used medications.
Contemporary Resistance Management
Clinical trials have shown that consulting specialists in HIV drug resistance improves virologic outcomes. A 2023 review reported that HIV drug resistance prevalence has declined in recent years as regimens with a higher barrier to resistance have become more widely used. At the same time, new antiretroviral drugs and formulations continue to become available for HIV prevention and management. These developments make resistance testing and expert interpretation important parts of contemporary care.
Why Resistance Testing Still Matters
HIV drug resistance remains a major global obstacle to successful and sustained antiretroviral therapy. Although treatment advances have improved outcomes, resistance can undermine the durability of a regimen. Global guidelines recommend antiretroviral drug-resistance testing in appropriate clinical circumstances. The continued recommendation reflects the risk that treatment choices made without resistance information may fail.
When Regimens Need to Change
A person with HIV may consider switching an antiretroviral regimen even when viral suppression is stable. The University of Washington's core concepts identify potential reasons for switching rather than treating suppression alone as the only consideration. The HIV Drug Resistance Database explains that three drug classes aim to inhibit viral replication, and that treatment failure or loss of response raises resistance concerns. Comparing regimen options therefore requires attention to both current suppression and the likely activity of available drug classes.
Why This Matters: Implications and Future Directions
The findings highlight the challenges of HIV drug resistance within PMTCT programs. Continued monitoring of resistance patterns is crucial for adapting treatment strategies.
Using History and Testing Together
Advanced HIV disease remains a major global health concern despite substantial progress in antiretroviral therapy. Recent expert guidance emphasizes using drug-resistance testing together with treatment history to guide therapy. A 2019 review also addressed resistance to antiretroviral drugs, methods for detecting it, and recommendations for testing and monitoring. Together, these sources support individualized treatment decisions based on both laboratory evidence and prior exposure to therapy.
Protecting Future Treatment Success
The CDC warns that HIV drug resistance threatens to undo decades of progress and that today's treatment successes could become tomorrow's failures without continued vigilance. A 2024 review describes how accumulating mutations can produce resistant viruses and eventually new subtypes, making antiretroviral medications ineffective. At the same time, resistance has declined in one reported analysis: combined NRTI and NNRTI resistance fell from 6.1% to 3.5% in HIV RNA and from 12.1% to 7.8% in HIV DNA between 2018 and 2024. The outlook therefore combines measurable progress with a continuing need for surveillance and improved detection.
Resistance Beyond the Clinic
HIV drug resistance in many low-income and middle-income countries has been described as a growing threat to the HIV response. The reported concern is that resistance could increase HIV-related mortality and undermine progress against the epidemic. Emerging pretreatment and transmitted resistance may also threaten the durability of existing regimens, particularly in low- and middle-income countries. These sources place resistance within broader health-system and access challenges rather than treating it as only a laboratory issue.
Resistance in Real Clinical Lives
Clinical case materials describe resistance developing during first-line therapy and during treatment with ritonavir-boosted protease inhibitors. Another case series examines optimization of therapy in both treatment-experienced and treatment-naive patients with HIV. These examples show that resistance management can involve changing or optimizing therapy for individual patients rather than applying one universal regimen. A 2018 analysis projected that unchecked resistance could result in 890,000 AIDS-related deaths and 450,000 new infections.
This study underscores the need for:
<ul><li><b>Improved surveillance:</b> Regularly monitoring HIVDR in mothers and infants.</li><li><b>Personalized Treatment:</b> Tailoring ART regimens based on individual resistance profiles.</li><li><b>Access to alternative drugs:</b> Providing options when first-line treatments fail due to resistance.</li></ul>